Slide 1: Q1 FY26 Earnings presentation
Q1 FY26 Earnings presentation May 5, 2026 © Solventum 2026. All rights reserved.
Slide 2: Forward-looking statements and use of document
Forward-looking statements and use of document This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934 that are subject to risks
Slide 3: Solventum | roadmap to the mission
Solventum | roadmap to the mission Values Strategic pillars Put people first Be a best & preferred Mission place to work Win with excellence Enabling better, Solve what matters smarter, safer Be a trusted partner healthcare to Advance together improve lives Be a top quartile Live with heart performe
Slide 4: Solventum value creation formula
Solventum value creation formula Attractive set up diverse businesses, attractive markets and strong brands Foundational + enhancements mission, talent, culture, innovation engine (commercial and R&D) market selection and growth drivers – enable sales growth, + Strategic clarity margin expansion and
Slide 5: Key Messages for the Quarter
Key Messages for the Quarter Strong execution Continued focus on portfolio to start the year optimization Balanced approach to Confident in capital achieving LRP allocation Q1 FY2026 Earnings Presentation © Solventum 2026. All rights reserved. 5 2See non-GAAP financial measures and reconciliation sc
Slide 6: Q1 FY26 financial summary
Q1 FY26 financial summary Key metrics Dental Solutions $354M GAAP Non-GAAP2 +7.9% Reported +3.4% Organic Operating margin 4.0% 19.5% Health Information TOTAL SOLVENTUM Systems MedSurg SALES $342M $1,234M Diluted EPS $0.07 $1.48 +4.1% Reported +4.7% Organic $2,007M +6.6% Reported (3.0)% Y/Y Reported
Slide 7: MedSurg summary
MedSurg summary AWC $497M | 40% +10.9% Y/Y Rep +2.1% Y/Y Org $1,234M Q1 financial results +6.6% Y/Y Reported +1.2% Y/Y Organic IP&SS Q1 FY26 Q1 FY25 Y/Y $737M | 60% +3.9% Y/Y Rep +0.6% Y/Y Org Reported +6.6% V.A.C.® Peel and Place Dressing Net sales $1,234M $1,157M Organic +1.2% First-ever up to 7-d
Slide 8: Dental Solutions summary
Dental Solutions summary Clinpro Clear Fluoride Treatment Provides effective fluoride uptake with lower dosage. Water-based, rosin-free formula Q1 financial results that’s ready to apply and provides protection to enamel and dentin surfaces. This fluoride treatment features a ready-release formula Q1
Slide 9: Health Information Systems summary
Health Information Systems summary Solventum System 360 Encompass Latest generation coding solution combines coding and reimbursement processes along Q1 financial results with workflow improvements to help hospitals streamline revenue cycle processes, receive accurate reimbursement, Q1 FY26 Q1 FY25
Slide 10: Executing a balanced capital plan
Executing a balanced capital plan Debt paydown Invest for growth Return capital to shareholders • Divested P&F business1; net proceeds • Announced and completed first • In Q1 2026, repurchased 923K shares primarily used for debt paydown acquisition, Acera Surgical; expanding for total consideration
Slide 11: FY2026 financial guidance and considerations
FY2026 financial guidance and Additional considerations considerations1 ERP timing impact Expect $100M+ of sales benefit in Q2 related to ERP timing Anticipate reversal of benefit, mostly in Q3, with no impact on full year Organic Organic sales growth +2.0% to +3.0% Sales Growth +3.0% to +4.0% exclu
Slide 12: Appendix
Appendix Q1 FY2026 Earnings Presentation © Solventum 2026. All rights reserved. 12
Slide 13: Non-GAAP financial measures
Non-GAAP financial measures In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adj
Slide 14: Q1 FY26 non-GAAP reconciliation & free cash flow
Q1 FY26 non-GAAP reconciliation & free cash flow 3M Spin-off & Purification separation-related Certain litigation- and Filtration Acquisition-related ($ Millions, except per share data) Q1 FY26 GAAP Amortization Restructuring costs costs related costs separation-related costs Q1 FY26 non-GAAP Net sa
Slide 15: Glossary and definitions
Glossary and definitions Abbreviation Elaboration Organic sales growth Total net sales less the impacts of foreign currency and sales from business acquisitions AI Artificial intelligence or divestitures for the first 12 months post-transaction AWC Advanced Wound Care Adjusted gross margin Gross mar